Sona Nanotech, Inc (TSE:SONA) has released an update.
Sona Nanotech, Inc. has secured a total of $40,000 in grant funding to enhance its intellectual property portfolio, with contributions from the NRC IRAP and Springboard Atlantic programs. The funds will aid in developing a robust IP strategy and the finalization of a provisional patent for a novel cancer drug delivery concept. The company’s CEO, David Regan, acknowledges the importance of this support for advancing their proprietary gold nanorod technology in cancer research and development.
For further insights into TSE:SONA stock, check out TipRanks’ Stock Analysis page.
